glp-1 analogue semaglutide Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit GLP-1 Receptor Agonists as Treatments

During shedding weight people must adapt to a new distribution of weight and changes in posture

The key strategies for minimizing regain during a short break include maintaining a high protein intake of 1.6-2.2 grams per kilogram of body weight daily, continuing or increasing resistance training to preserve muscle mass, planning meals in advance so hunger does not drive impulsive food choices, monitoring weight weekly but not daily to avoid overreacting to normal fluctuations, and staying hydrated since the body may retain more water without GLP-1 mediated effects on fluid balance

The decrease in mean GFR at 52 weeks was smaller in the high (1.5 mg) and low dose dulaglutide (0.75 mg) treatment groups (both 0.7 ml/min/1.73 m2) vs

Semaglutide was FDA-approved to treat obesity in 2021

Jaworski said

If electrolyte supplementation brings noticeable relief within two to three days, electrolyte depletion was likely your primary fatigue driver